Clicky

Prof. Dott. Celestino Sardu Partecipazione a congressi

Webinar internazionale di The Journal of Cardiovascular Aging

Il Prof. Celestino Sardu relatore al webinar internazionale di The Journal of Cardiovascular AgingIl 14 ottobre 2026, il Prof. Celestino Sardu, Professore Associato presso l'Università degli Studi della Campania “Luigi Vanvitelli”, partecipa in qualità di relatore a un webinar scientifico internazionale promosso dalla rivista The Journal of Cardiovascular Aging, dedicato…
Read More
Prof. Dott. Celestino Sardu Partecipazione a congressi

Prof. Celestino Sardu a Hot Topics in Cardiodiabetologia

Il 2 ottobre 2026, presso Palazzo Alabardieri a Napoli, si è tenuto l’evento “Hot Topics in Cardiodiabetologia – Strategie integrate per la gestione delle comorbidità cardiometaboliche”, un momento di confronto dedicato ai principali temi emergenti nell’ambito della cardiodiabetologia. L’incontro ha riunito professionisti e specialisti con l’obiettivo di favorire il confronto…
Read More
Prof. Dott. Celestino Sardu Pubblicazioni Scientifiche

Microplastics in human lung tissue from autopsy samples collected in 1991 and 2024

Microplastics in human lung tissue from autopsy samples collected in 1991 and 2024: a comparative post-mortem study Abstract Background: Environmental accumulation and human exposure to microplastics MPs are increasing. It is not known whether there is a higher bioaccumulation of microplastics (MPs) in human lungs collected recently and compared with those…
Read More
Prof. Dott. Celestino Sardu Pubblicazioni Scientifiche

Salute cardiovascolare tra diabete e MASLD: un paradigma emergente

Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm Abstract Background. The coexistence of type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular disease describes a clinical profile encountered very frequently in daily practice. Besides being highly prevalent, this combination is…
Read More
Prof. Dott. Celestino Sardu Pubblicazioni Scientifiche

Studio GLISCAR: le gliflozine migliorano il rimodellamento del cuore destro nel diabete tipo 2 con scompenso

Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study Abstract Aims. The influence of sodium-glucose cotransporter 2 inhibitors (SGLT2i), added to optimal medical therapy, on right ventricular systolic function in heart failure with reduced ejection fraction…
Read More
Prof. Dott. Celestino Sardu Pubblicazioni Scientifiche

GLP-1 RA e dilatazione dell’aorta ascendente nel diabete tipo 2: i risultati di uno studio prospettico

GLP-1 Receptor Agonists Are Associated with Reduced Ascending Aorta Dilatation in Patients with Type 2 Diabetes: A Prospective Study Abstract Background. Subclinical dilatation of the ascending aorta is a frequent and often overlooked finding in patients with type 2 diabetes, and no medical therapy has so far been shown to…
Read More
Prof. Dott. Celestino Sardu Pubblicazioni Scientifiche

Vascolarizzazione intra-placca all’ecografia con contrasto: predice gli eventi cardiovascolari nel diabete tipo 2

Intra-plaque vascularization assessed in contrast-enhanced ultrasound predicts cardiovascular events in type 2 diabetes with no significant carotid atherosclerotic stenosis: a prospective study with therapeutic implications for SGLT2 inhibitor use Abstract Aims. People with type 2 diabetes and no significant carotid stenosis are usually classified at moderate cardiovascular risk, yet some…
Read More
Prof. Dott. Celestino Sardu Pubblicazioni Scientifiche

Studio IMAGIN: empagliflozin in aggiunta a metformina rallenta la progressione della MASLD nel diabete tipo 2

Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study Abstract Background and aim. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most frequent cause of chronic liver disease. The IMAGIN study compared the effect of adding empagliflozin to metformin…
Read More
1 2 3 … 5
Chiama ora
WhatsApp